Abstract
22-oxacalcitriol (OCT) is a vitamin D3 analog and a vitamin D receptor activator (VDRA) that is used as a drug for secondary hyperparathyroidism (SHPT) and has been available clinically in Japan since 2000. The pharmacological characteristics of OCT include rapid clearance from the systemic circulation compared to that of calcitriol, good tissue distribution, and relatively long retention in the nucleus in parathyroid cells. In clinical studies, OCT has been shown to decrease the parathyroid hormone (PTH) level with an effect equivalent to that of calcitriol. Other reports show that OCT produces superior improvement of bone metabolism compared to calcitriol. Treatment with ultrasound-guided direct injection of OCT into the parathyroid has also been attempted. In animal studies, OCT does not influence the blood Ca or P level and is less likely to promote progression of calcification in cardiovascular tissue. The influence of VDRAs including OCT on the progression of cardiovascular lesions and survival in SHPT patients requires further studies.
Keywords: Maxacalcitriol, percutaneous VDRA injection therapy, secondary hyperparathyroidism, vitamin D analogs, vitamin D receptor activator, 22-oxacalcitriol.
Current Vascular Pharmacology
Title:Clinical Uses of 22-Oxacalcitriol
Volume: 12 Issue: 2
Author(s): Masahide Mizobuchi and Hiroaki Ogata
Affiliation:
Keywords: Maxacalcitriol, percutaneous VDRA injection therapy, secondary hyperparathyroidism, vitamin D analogs, vitamin D receptor activator, 22-oxacalcitriol.
Abstract: 22-oxacalcitriol (OCT) is a vitamin D3 analog and a vitamin D receptor activator (VDRA) that is used as a drug for secondary hyperparathyroidism (SHPT) and has been available clinically in Japan since 2000. The pharmacological characteristics of OCT include rapid clearance from the systemic circulation compared to that of calcitriol, good tissue distribution, and relatively long retention in the nucleus in parathyroid cells. In clinical studies, OCT has been shown to decrease the parathyroid hormone (PTH) level with an effect equivalent to that of calcitriol. Other reports show that OCT produces superior improvement of bone metabolism compared to calcitriol. Treatment with ultrasound-guided direct injection of OCT into the parathyroid has also been attempted. In animal studies, OCT does not influence the blood Ca or P level and is less likely to promote progression of calcification in cardiovascular tissue. The influence of VDRAs including OCT on the progression of cardiovascular lesions and survival in SHPT patients requires further studies.
Export Options
About this article
Cite this article as:
Mizobuchi Masahide and Ogata Hiroaki, Clinical Uses of 22-Oxacalcitriol, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/15701611113119990023
DOI https://dx.doi.org/10.2174/15701611113119990023 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry The Vectorcardiogram and the Main Dromotropic Disturbances
Current Cardiology Reviews Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) A Proposal----The Renal Kallikrein-Kinin System as a Compensating System for Salt Accumulation after Excess Salt Intake
Current Hypertension Reviews Severity Evaluation of Regional Cerebrovascular Reactivity in Acute Stroke Patients Using SPECT
Current Medical Imaging Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]
Current Vascular Pharmacology Pleiotropic Effects of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors: Candidate Mechanisms for Anti-Lipid Deposition in Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Hyperglycaemia and the Ischaemic Brain: Continuous Glucose Monitoring and Implications for Therapy
Current Diabetes Reviews Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy Passage of VIP / PACAP / Secretin Family Across the Blood-Brain Barrier: Therapeutic Effects
Current Pharmaceutical Design Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol
Current Drug Metabolism Editorial [Hot Topic: Neural Control of the Vasculature: Pharmacological Targets in Vascular Disease (Guest Editors: Andrzej Loesch and Michael R. Dashwood)]
Current Vascular Pharmacology C-Methionine PET/CT in Central Nervous System Tumours: A Review
Current Radiopharmaceuticals Editorial: Review on Intracerebral Haemorrhage: Multidisciplinary Approaches to the Injury Mechanism Analysis and Therapeutic Strategies
Current Pharmaceutical Design A Polyphenolic Complex Attenuates Inflammatory Response and Blood- Brain Barrier Disruption
Current Neurovascular Research Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Lipid Nanoparticles for the Delivery of Active Natural Medicines
Current Pharmaceutical Design Effect of S-equol and Soy Isoflavones on Heart and Brain
Current Cardiology Reviews Bleeding Complications in the Course of Treatment with Antidepressants in Elderly Patients
Current Psychiatry Reviews